Cocrystal Pharma, Inc. (COCP)

NASDAQ • Currency in USD

$1.44

-$0.02

-1.37%

Last Update: 11 Sept 2025, 20:00

$14.76M

Market Cap

-0.99

P/E Ratio (TTM)

—

Forward Dividend Yield

$1.12 - $3.26

52 Week Range

COCP Stock Price Chart

Explore Cocrystal Pharma, Inc. interactive price chart. Choose custom timeframes to analyze COCP price movements and trends.

COCP Company Profile

Discover essential business fundamentals and corporate details for Cocrystal Pharma, Inc. (COCP) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

22 Feb 2012

Employees

11.00

Website

https://www.cocrystalpharma.com

CEO

Sam Lee

Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

COCP Financial Timeline

Browse a chronological timeline of Cocrystal Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 13 May 2026

Upcoming earnings on 12 Nov 2025

EPS estimate is -$0.21.

Earnings released on 14 Aug 2025

EPS came in at -$0.20 surpassing the estimated -$0.30 by +33.33%.

Earnings released on 15 May 2025

EPS came in at -$0.23 surpassing the estimated -$0.52 by +55.77%.

Earnings released on 31 Mar 2025

EPS came in at -$0.32 surpassing the estimated -$0.55 by +41.82%, while revenue for the quarter reached $136.00K .

Earnings released on 13 Nov 2024

EPS came in at -$0.49 surpassing the estimated -$0.57 by +14.04%.

Earnings released on 14 Aug 2024

EPS came in at -$0.53 falling short of the estimated -$0.51 by -3.92%.

Earnings released on 13 May 2024

EPS came in at -$0.39 surpassing the estimated -$0.54 by +27.78%.

Earnings released on 28 Mar 2024

EPS came in at -$0.44 surpassing the estimated -$0.57 by +22.81%, while revenue for the quarter reached $144.00K .

Earnings released on 13 Nov 2023

EPS came in at -$0.41 surpassing the estimated -$0.47 by +12.77%.

Earnings released on 14 Aug 2023

EPS came in at -$0.50 surpassing the estimated -$0.53 by +5.66%.

Earnings released on 15 May 2023

EPS came in at -$0.64 falling short of the estimated -$0.59 by -8.47%.

Earnings released on 29 Mar 2023

EPS came in at -$0.55 surpassing the estimated -$0.72 by +23.61%.

Earnings released on 14 Nov 2022

EPS came in at -$0.70 falling short of the estimated -$0.49 by -42.86%.

Stock split effective on 11 Oct 2022

Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 15 Aug 2022